FDA Brief

Warning letters Drugs

FDA warning letter to

Green Vitality dba Gr33n

High riskIssued Aug 25, 2025Posted Sep 2, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Green Vitality dba Gr33n that its Jimerito Honey Eye Drops are an unapproved new drug sold with disease-treatment claims.

What happened

In June 2025, FDA reviewed the website gr33n.com and the Instagram account trygr33n and found Jimerito Honey Eye Drops offered for sale in the United States. FDA cited website and social media claims that the product treats or prevents eye problems such as cataracts, glaucoma, floaters, blurry vision, eye fatigue, and eye discomfort. FDA determined the product is a drug and an unapproved new drug with no FDA-approved application.

What FDA found

  1. Jimerito Honey Eye Drops is a drug because the website and Instagram posts say it treats or prevents eye diseases and affects eye function.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. The product is a new drug because it is not generally recognized as safe and effective for those uses.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  3. There is no FDA-approved application for the product, so selling it across state lines violates the law.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)

What FDA wants

FDA asks Green Vitality to notify it in writing within 15 working days of the specific steps taken to correct the violations, including an explanation and documentation to prevent recurrence. If the company believes there is no violation, it must give its reasoning and supporting information; if it cannot complete corrections in that time, it must state why and when it will finish.

Who should pay attention

  • online sellers of eye drops and supplements
  • brands using disease-treatment claims in social media ads
  • consumers considering unapproved eye products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk